NovImmune inks deal, eyes possible IPO

Genentech has forged a licensing pact with Geneva-based NovImmune for an early-stage IL-17 antibody that may be useful in treating inflammatory and autoimmune diseases. And the Swiss biotech, which has raised SFR$154 million, says the deal may help advance plans for a possible IPO. Story

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."